A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding.
Potent neutralizing antibodies (Abs) have been proven with therapeutic efficacy for the intervention against SARS-CoV-2. Majority of these Abs function by directly interfering with the virus entry to host cells. Here, we identified a receptor binding domain (RBD) specific monoclonal Ab (mAb) 82A6 with efficient neutralizing potency against authentic SARS-CoV-2 ... virus. As most Abs targeting the non-receptor binding motif (RBM) region, 82A6 was incapable to block the RBD-ACE2 interaction. In particular, it actively promoted the S1 subunit shedding from the S protein, which may lead to effective reduction of intact SARS-CoV-2 viruses. Importantly, it could block potential syncytia formation associated with post-infectious cell surface expression of S proteins. Our study evidenced a RBD specific Ab with unique beneficial efficacy against SARS-CoV-2 infection, which might bring informative significance to understand the collective effects of neutralizing Abs elicited in COVID-19 patients.
Mesh Terms:
Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Antibody Specificity, Binding Sites, COVID-19, COVID-19 Serotherapy, Giant Cells, HEK293 Cells, Humans, Immunization, Passive, In Vitro Techniques, Protein Domains, Protein Subunits, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Virus Shedding
Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Antibody Specificity, Binding Sites, COVID-19, COVID-19 Serotherapy, Giant Cells, HEK293 Cells, Humans, Immunization, Passive, In Vitro Techniques, Protein Domains, Protein Subunits, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Virus Shedding
Biochem Biophys Res Commun
Date: Sep. 24, 2021
PubMed ID: 34325131
View in: Pubmed Google Scholar
Download Curated Data For This Publication
245578
Switch View:
- Interactions 1